No Data
China National Medicines Corporation (600511) 2024 Third Quarter Report Review: Steady growth in Q3 revenue with some improvement in operational capability.
Investment Highlights: Event: The company announced the 24Q3 performance, with the company achieving revenue of 38.029 billion yuan (+4.1%) during the reporting period, net income attributable to the parent company of 1.481 billion yuan (+1.3%), and non-net income attributable to the parent company of 14.89 billion yuan.
China National Medicines' Q3 Profit Rises Marginally; Shares Fall 6%
Sinopharm: Sinopharm Report for the Third Quarter of 2024
Sinopharm Report for the Third Quarter of 2024
China National Medicines Corporation (01099.HK) earned 1.481 billion RMB in the first nine months, a growth of 1.3%.
Sinopharm (01099.HK) announced the performance of its subsidiary China National Medicines Corporation (600511.SH) for the first nine months, with revenue of 38.029 billion RMB (same below), an annual increase of 4.1%. Net profit attributable to shareholders was 1.481 billion yuan, an increase of 1.3%, with an EPS of 1.9632 yuan.
Express News | China National Medicines Corporation: The net income for the first three quarters was 1.481 billion yuan, a year-on-year increase of 1.3%.
No Data
No Data